Company Encyclopedia
View More
name
Atara Biotherap
ATRA.US
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research.
1.946 T
ATRA.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking141/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-36.80%E
    • Profit Margin15.40%A
    • Gross Margin12.40%D
  • Growth ScoreA
    • Revenue YoY51.27%A
    • Net Profit YoY117.57%A
    • Total Assets YoY-78.86%E
    • Net Assets YoY59.54%A
  • Cash ScoreB
    • Cash Flow Margin649.25%C
    • OCF YoY51.27%A
  • Operating ScoreA
    • Turnover1.76A
  • Debt ScoreE
    • Gearing Ratio221.44%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Atara Biotherapeutics Chief Accounting Officer Yanina Grant-Huerta Reports Disposal of Common Shares

    Yanina Grant-Huerta, Chief Accounting Officer of Atara Biotherapeutics Inc., reported the disposal of common shares. The filing is available via EDGAR, the SEC's system. This AI-generated news is for informational purposes and not financial advice.

    Reuters·
    US
    ATRA
    +13.15%
    Reuters·
    US
    ATRA
    +13.15%

    Officer Grant-Huerta Files To Sell 2,069 Of Atara Biotherapeutics Inc [ATRA]

    Officer Grant-Huerta of Atara Biotherapeutics Inc filed a Form 144 with the SEC to sell 2,069 restricted shares on November 17, 2025, through Morgan Stanley Smith Barney LLC. The filing allows the sale within 90 days.

    Reuters·
    US
    ATRA
    +13.15%
    Reuters·
    US
    ATRA
    +13.15%

    Atara Biotherap | 10-Q: FY2025 Q3 Revenue Beats Estimate at USD 3.453 M

    LB filings·
    US
    ATRA
    +13.15%
    LB filings·
    US
    ATRA
    +13.15%

    Atara Biotherap | 8-K: FY2025 Q3 Revenue Beats Estimate at USD 3.453 M

    LB filings·
    US
    ATRA
    +13.15%
    LB filings·
    US
    ATRA
    +13.15%

    Atara Biotherapeutics Q3 EPS USD -0.32

    Nov 12 (Reuters) - Atara Biotherapeutics Q3 operating income USD -3.574 million. * Q3 net income USD -4.303 million * Q3 revenue USD 3.453 million

    Reuters·
    US
    ATRA
    +13.15%
    Reuters·
    US
    ATRA
    +13.15%
    © 2025 Longbridge｜Disclaimer